IPH.PA - Innate Pharma S.A.

Paris - Paris Delayed Price. Currency in EUR
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue65,72125,1417,62316,651
Cost of Revenue48,62829,90622,67110,698
Gross Profit17,093-4,765-15,0485,953
Operating Expenses
Research Development----
Selling General and Administrative9,5226,0084,9187,554
Non Recurring----
Total Operating Expenses58,15035,91427,58919,441
Operating Income or Loss7,571-10,773-19,966-2,790
Income from Continuing Operations
Total Other Income/Expenses Net5,3704,067319-102
Earnings Before Interest and Taxes7,571-10,773-19,966-2,790
Interest Expense-124-139-165-194
Income Before Tax12,941-6,706-19,647-2,892
Income Tax Expense301---
Minority Interest----
Net Income From Continuing Ops12,640-6,706-19,647-2,892
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income12,640-6,706-19,647-2,892
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares12,640-6,706-19,647-2,892